177 related articles for article (PubMed ID: 34003067)
21. Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia.
Cesarec A; Likić R
Appl Health Econ Health Policy; 2017 Apr; 15(2):277-286. PubMed ID: 27730538
[TBL] [Abstract][Full Text] [Related]
22. Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting.
Barat EC; Arrii MLE; Soubieux-Bourbon A; Daouphars M; Varin R; Tilleul PR
Breast; 2023 Dec; 72():103588. PubMed ID: 37857129
[TBL] [Abstract][Full Text] [Related]
23. Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population.
Gagliato D; Reinert T; Rocha C; Tavares M; Pimentel S; Fuzita W; Araújo M; Matias D; Aleixo S; França B; Magaton É; Brito N; Cardoso AC; Castilho V
Oncol Ther; 2024 Jun; ():. PubMed ID: 38836997
[TBL] [Abstract][Full Text] [Related]
24. Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study.
Smyth LM; Iyengar NM; Chen MF; Popper SM; Patil S; Wasserheit-Lieblich C; Argolo DF; Singh JC; Chandarlapaty S; Sugarman SM; Comen EA; Drullinsky PR; Traina TA; Troso-Sandoval T; Baselga J; Norton L; Hudis CA; Dang CT
Breast Cancer Res Treat; 2016 Jul; 158(1):91-97. PubMed ID: 27306421
[TBL] [Abstract][Full Text] [Related]
25. Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment.
McBride A; MacDonald K; Fuentes-Alburo A; Abraham I
J Med Econ; 2021; 24(1):598-606. PubMed ID: 33866947
[TBL] [Abstract][Full Text] [Related]
26. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz.
McBride A; Balu S; Campbell K; Bikkina M; MacDonald K; Abraham I
Future Oncol; 2017 Oct; 13(25):2285-2295. PubMed ID: 28870106
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy and Safety of Trastuzumab Biosimilars in Combination with Pertuzumab].
Shinada M; Okuda Y; Mikame Y; Kezuka C; Suga R; Saitou T; Kobayashi N; Hoshi C; Imai Y
Gan To Kagaku Ryoho; 2023 May; 50(5):615-618. PubMed ID: 37218323
[TBL] [Abstract][Full Text] [Related]
28. Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv.
MacDonald K; McBride A; Alrawashdh N; Abraham I
J Med Econ; 2020 Dec; 23(12):1466-1476. PubMed ID: 33023360
[TBL] [Abstract][Full Text] [Related]
29. Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma.
McBride A; MacDonald K; Abraham I
Leuk Res; 2021 Jul; 106():106591. PubMed ID: 33957339
[TBL] [Abstract][Full Text] [Related]
30. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.
Shao Z; Pang D; Yang H; Li W; Wang S; Cui S; Liao N; Wang Y; Wang C; Chang YC; Wang H; Kang SY; Seo JH; Shen K; Laohawiriyakamol S; Jiang Z; Li J; Zhou J; Althaus B; Mao Y; Eng-Wong J
JAMA Oncol; 2020 Mar; 6(3):e193692. PubMed ID: 31647503
[TBL] [Abstract][Full Text] [Related]
31. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E;
JAMA; 2017 Jan; 317(1):37-47. PubMed ID: 27918780
[TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
Wang B; Deng R; Hennig S; Badovinac Crnjevic T; Kaewphluk M; Kågedal M; Quartino AL; Girish S; Li C; Kirschbrown WP
Cancer Chemother Pharmacol; 2021 Sep; 88(3):499-512. PubMed ID: 34106303
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results.
Perez EA; López-Vega JM; Petit T; Zamagni C; Easton V; Kamber J; Restuccia E; Andersson M
Breast Cancer Res; 2016 Dec; 18(1):126. PubMed ID: 27955684
[TBL] [Abstract][Full Text] [Related]
35. Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer.
Swain SM; Tan AR; Gianni L; Kuemmel S; Dang CT; Schneeweiss A; O'Shaughnessy J; Liu H; Aguila C; Heeson S; Macharia H; Yang K; Restuccia E; Loibl S
Eur J Cancer; 2023 Jan; 178():70-81. PubMed ID: 36410207
[TBL] [Abstract][Full Text] [Related]
36. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
O'Shaughnessy J; Sousa S; Cruz J; Fallowfield L; Auvinen P; Pulido C; Cvetanovic A; Wilks S; Ribeiro L; Burotto M; Klingbiel D; Messeri D; Alexandrou A; Trask P; Fredriksson J; Machackova Z; Stamatovic L;
Eur J Cancer; 2021 Jul; 152():223-232. PubMed ID: 34147014
[TBL] [Abstract][Full Text] [Related]
37. Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.
Kuemmel S; Tondini CA; Abraham J; Nowecki Z; Itrych B; Hitre E; Karaszewska B; Juárez-Ramiro A; Morales-Vásquez F; Pérez-García JM; Cardona-Huerta S; Monturus E; Sequi M; Restuccia E; Benyunes M; Martín M
Breast Cancer Res Treat; 2021 Jun; 187(2):467-476. PubMed ID: 33748921
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer.
Leung JH; Tai YS; Wang SY; Yip Fion HT; Tsung-Chin H; Chan AL
Breast; 2022 Oct; 65():91-97. PubMed ID: 35870421
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study).
Yamashita T; Kawaguchi H; Masuda N; Kitada M; Narui K; Hattori M; Yoshinami T; Matsunami N; Yanagihara K; Kawasoe T; Nagashima T; Bando H; Yano H; Hasegawa Y; Nakamura R; Kashiwaba M; Morita S; Ohno S; Toi M
Invest New Drugs; 2021 Feb; 39(1):217-225. PubMed ID: 32833136
[TBL] [Abstract][Full Text] [Related]
40. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries.
Abraham I; Han L; Sun D; MacDonald K; Aapro M
Future Oncol; 2014; 10(9):1599-609. PubMed ID: 25145430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
